Similarly, treatment with GLP-1 agonists was shown to prevent T2DM-associated autophagy impairments in the brain in vivo (Candeias et al., 2018; Zhang M. et al., 2021). This evidence concerns the gene GCG and type 2 diabetes mellitus.